Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+)
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years
حداقل ۳ — حداکثر ۲۰ • واحد: g/dL
حداقل ۰.۱ — حداکثر ۵۰۰ • واحد: ×10⁹/L
حداقل ۱ — حداکثر ۲۰۰۰ • واحد: ×10⁹/L
حداقل ۰ — حداکثر ۱۰۰ • واحد: %
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–2
- Intermediate-1 Risk3–4
- Intermediate-2 Risk5–6
- High Risk7–15
The Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include age years. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Stratifies risk for patients with overt primary myelofibrosis (PMF) using clinical, laboratory, and molecular genetic parameters. This enhanced prognostic system incorporates high molecular risk mutations to improve risk stratification beyond traditional clinical factors.
Clinical Indication
The Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+) is indicated for bedside clinical practice to support Stratifies risk for patients with overt primary myelofibrosis (PMF) using clinical, laboratory, and molecular genetic parameters. This enhanced prognostic system incorporates high molecular risk mutations to improve risk stratification beyond traditional clinical factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Risk categories guide treatment decisions including timing of allogeneic stem cell transplantation.
MIPSS70 score = Age points + Hemoglobin points + WBC points + Platelet points + Blast points + Constitutional symptoms points + High molecular risk points (+ Very high molecular risk points for MIPSS70+)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age_years | integer | Yes | Patient age in years. Age is a key prognostic factor in primary myelofibrosis(years) |
| hemoglobin | float | Yes | Hemoglobin level in g/dL. Anemia is an independent prognostic factor in myelofibrosis(g/dL) |
| white_blood_count | float | Yes | White blood cell count in ×10⁹/L. Leukocytosis indicates disease burden and poor prognosis(×10⁹/L) |
| platelet_count | float | Yes | Platelet count in ×10⁹/L. Thrombocytopenia is associated with advanced disease and poor prognosis(×10⁹/L) |
| circulating_blasts | float | Yes | Percentage of circulating blasts in peripheral blood. Higher blast percentage indicates disease progression(%) |
| constitutional_symptoms | string | Yes | Presence of constitutional symptoms (weight loss >10% in 6 months, night sweats, fever). Indicates advanced disease |
| high_molecular_risk_mutations | string | Yes | Presence of high molecular risk mutations (ASXL1, EZH2, SRSF2, IDH1/2). These mutations confer poor prognosis |
| very_high_molecular_risk | string | No | Presence of very high molecular risk mutations (≥2 high-risk mutations or specific mutation patterns). Used in MIPSS70+ version |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–2 | Low Risk | Low risk primary myelofibrosis |
| 3–4 | Intermediate-1 Risk | Intermediate-1 risk primary myelofibrosis |
| 5–6 | Intermediate-2 Risk | Intermediate-2 risk primary myelofibrosis |
| 7–15 | High Risk | High risk primary myelofibrosis |
Evidence-Based References (EBM)
- Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310-318. doi: 10.1200/JCO.2017.76.4886.DOI: 10.1200/JCO.2017.76.4886
- Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol. 2018;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867.DOI: 10.1200/JCO.2018.78.9867
- Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-8. doi: 10.1182/blood-2009-09-245837.DOI: 10.1182/blood-2009-09-245837
Related calculators
- WHO Diagnostic Criteria for Polycythemia Vera (2016)
- DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis
- GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis
- Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM)
- International Consensus Classification (ICC) Diagnostic Criteria for Primary Myelofibrosis (PMF)